A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair. (NEOART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04145544|
Recruitment Status : Recruiting
First Posted : October 30, 2019
Last Update Posted : September 8, 2021
The objective of this study is to evaluate the safety and effectiveness of ArtiFascia® in comparison with commercially available dural substitutes in patients requiring Dural repair following neurosurgery.
Patients with planned cranial neurosurgery can take part in this study. During the surgery the soft membrane that covers the brain (called dura) is likely to be cut and damaged. A damaged dura can cause a leakage of brain fluids (cerebrospinal fluid [CSF] leakage) and increase the risk of infections. Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a medical synthetic dural substitute that is absorbed by the body. ArtiFascia® supports the re-formation of a new dura. In addition it has a sealant layer that can reduce CSF leakage and infection.
|Condition or disease||Intervention/treatment||Phase|
|Dural Tear Cerebrospinal Fluid Leak||Device: Implantation of the ArtiFascia® Device: Implantation of other commercial suturable dural substitute||Not Applicable|
A Prospective, randomized, controlled multi-center study of ArtiFascia® Dural repair patch compared with commercially available dural substitutes- NEOART Study.
The dura mater is a fibrous connective tissue that surrounds the nervous system (brain and spinal cord) and provides a mechanical barrier that contains the cerebrospinal fluid (CSF). The dura mater may be damaged as a result of trauma or planned surgery. When dural defects cannot be repaired by primary closure, a dural substitute must be utilized in order to reduce CSF leakage.
There are devices that have been used as dural substitutes. Among the devices that are based on natural raw materials, collagen-based matrices are widely used. Although collagen was proven to be biocompatible, using collagen-based materials still possess several limitations such as CSF leaks. Synthetic dural substitutes are also used to repair dura mater. The most widely used raw-material for these synthetic products are polyesters - resorbable and biocompatible polymers. There are several dural substitutes based on synthetic polyesters that were successfully tested pre-clinically as well as in human studies.
Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a medical synthetic dural substitute that is absorbed by the body.
Before the study, the patients will have their blood taken and they will undergo neurological assessment. If they are suitable to participate in the study, and agree to participate, they will be randomly allocated into one of the following groups:
- Experimental group (ArtiFascia® device);
- Control group (Other commercially available suturable dural substitutes).
The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use ArtiFascia® patch or standard dural substitute to repair the damaged Dura. ArtiFascia® graft will be placed in areas where the native dural layer was damaged or missing. ArtiFascia® will be applied via a routine and well-known procedure, using a suturing technique. After implantation, the porous fibrous structure of ArtiFascia® provides a scaffold, which enables infiltration of fibroblasts and cells from the intact tissue, ultimately replacing damaged dural tissue. The patch is expected to resorb within a few months and to be replaced by the native tissue with complete dural closure.
During the surgery and until patient's release from the hospital the patient's health will be closely monitored. Before the discharge patients will have to undergo neurological examination. Patients will be obligated to attend the follow up visits after the surgery at the dates scheduled by the attending physician.
At each of the visits physical and neurological examinations will be performed. Radiographic Evaluation (Magnetic Resonance Imaging) will be performed also 6 months post operation.
A total of 90 patients will be enrolled and implanted with test or control device. Up to 10 centers in Europe and Israel are planned to participate in this study.
The primary endpoint will be achieved when the final study subject has completed a 6-months follow-up.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes- NEOART Study.|
|Actual Study Start Date :||January 7, 2020|
|Estimated Primary Completion Date :||November 2021|
|Estimated Study Completion Date :||May 2022|
Experimental: Treatment arm
Procedure will be performed under general anaesthesia. The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use the ArtiFascia® patch. Implantation of the ArtiFascia® will be according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Detailed instructions are in the instructions for use.
Post operation the subject will stay at the hospital according to site standards and physician discretion.
Device: Implantation of the ArtiFascia®
Following are the general instructions for use for the ArtiFascia®:
Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.
Active Comparator: Control
Same procedure as for the treatment arm but using a commercial suturable dural substitute.
Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use.
Device: Implantation of other commercial suturable dural substitute
Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
- Assess the safety and effectiveness of ArtiFascia® in comparison with commercially available suturable dural substitutes in subjects requiring Dural repair following neurosurgery [ Time Frame: The rate of adverse events, adverse device effects and device deficiencies will be assessed on a continuous basis from the baseline (following signing the ICF) through the study completion at 6 month. ]Safety and effectiveness will be assessed by evaluating the absence of CSF fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging. During MRI imaging CSF leakage will be assessed as: none/external leakage/subgaleal leakage. Additional if leakage is present, severity will be reported (mild/moderate/severe).
- Wound healing assessment [ Time Frame: 6 month follow-up ]Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.
- Device Handling Characteristics [ Time Frame: 6 month follow-up ]Based on scale to evaluate device feasibility: cutting, suturing, seal quality, overall handling (Score from 1=easy to 5=difficult).
- Radiographic evaluation (Magnetic Resonance Imaging). [ Time Frame: 6 month follow-up ]To determine the presence or absence of the following measure: adhesion formation, new tissue formation, pseudomeningocele, extracerebal fluid collection and brain edema adjacent to device implant size Measurements will be done based on MRI imaging (X,Y,Z axis; in milimeters).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04145544
|Contact: Amir Bahar, Ph.D||+972 email@example.com|
|Contact: Joseph Milbaum, MD||+972 firstname.lastname@example.org|
|Genk, Belgium, B-3600|
|Contact: Frank Weyns, Prof Frank.Weyns@zol.be|
|Contact: Celine Quix email@example.com|
|St. Anne's University Hospital Brno||Recruiting|
|Brno, Czechia, 656 91|
|Contact: Radim Jancalek, Prof, PhD firstname.lastname@example.org|
|Contact: Veronica Kubickova email@example.com|
|Neurochirurgická klinika Přednosta FN Olomouc||Recruiting|
|Olomouc, Czechia, 779 00|
|Contact: Miroslav Vaverka, Prof firstname.lastname@example.org|
|Contact: Matej Halaj email@example.com|
|Rabin Medical Center (Beilinson, Hasharon)||Recruiting|
|Petah Tikva, Israel, 49100|
|Contact: Giorgio Rubin, MD firstname.lastname@example.org|
|Contact: Keren Melke email@example.com|
|Medical University of Gdańsk||Recruiting|
|Gdańsk, Poland, 80-214|
|Contact: Paweł Słoniewski, Prof firstname.lastname@example.org|
|Barlicki University Hospital||Recruiting|
|Łódź, Poland, 90-153|
|Contact: Dariusz Jaskólski, Prof. email@example.com|
|Contact: Jan Fortuniak, MD firstname.lastname@example.org|
|Hospital Universitari Vall d'Hebron||Recruiting|
|Barcelona, Spain, 08035|
|Contact: Antonia Maria Poca Pastor, Prof email@example.com|
|Contact: Lavinia Herea firstname.lastname@example.org|
|Hospital Clinic de Barcelona||Recruiting|
|Barcelona, Spain, 08036|
|Contact: Joaquim Enseñat, MD email@example.com|
|Contact: Sara Domenech firstname.lastname@example.org|
|Hospital Universitario de Bellvitge||Recruiting|
|Barcelona, Spain, 09807|
|Contact: Andreu Gabarrós, MD email@example.com|
|Contact: Alberto Pérez Giraldo firstname.lastname@example.org|